Real Housewives of New Jersey” star Jennifer Fessler didn’t follow her doctor’s advice when she started taking a GLP-1 weight ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

CHICAGO — Semaglutide, a glucagon-like peptide (GLP-1) receptor agonist, has shown convincing benefits in yet another population: patients with peripheral arterial disease (PAD). In the STRIDE ...

A new international study has found that semaglutide, a medication commonly used to treat type 2 diabetes and obesity, ...

Compounded semaglutide and Ozempic are different products. While both may be used in people with type 2 diabetes, Ozempic is approved by the FDA, but compounded semaglutide is not. Compounded ...

Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with ...

Semaglutide was initially approved under the brand name Ozempic for Type 2 diabetes, while the brand name Wegovy is only approved for weight loss. Here, we’ll compare tirzepatide (Zepbound ...

INDIANAPOLIS – The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs were taken off the FDA’s shortage list. Hundreds of ...

The side effects of Ozempic (semaglutide) can include abdominal (belly) pain, diarrhea, nausea, and vomiting, among other digestive-related problems. Ozempic is not a high-risk medication for most ...

Semaglutide 2.4 mg reduced total cardiovascular events by 22% in people with established cardiovascular disease (CVD) and overweight or obesity without diabetes. 1 Obesity directly leads to ...

Semaglutide, the medication better known as ... It arises when narrowed arteries restrict blood flow to the arms and legs. Diabetes raises the risk of PAD, but the condition can afflict people ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges. Find out who is the winner.